New health guidelines in England allow access to the CRISPR gene editing therapy exagamglogene autotemcel (exa-cel) for severe sickle cell disease, marking a significant shift in treatment. The therapy, priced at £1.6 million, offers hope for patients who cannot find suitable stem cell donors. While it represents a breakthrough, uncertainties about its long-term effectiveness and safety remain. Teljes cikk (Euronews.com)